Page 106

Febrero 2016

ARTÍCULOS DE REVISIÓN Hidroxicloroquina en enfermedades autoinmunes sistémicas - Á. Danza et al 38. Rihl M, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren’s syndrome. Rheumatology (Oxford) 2009; 48 (7): 796-9. 39. Ramos-Casals M, Tzioufas AG, Stone JH, Sisó A, Bosch X. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304 (4): 452-60. 40. Loudon JR. Hydroxychloroquine and postoperative thromboembolism after total hip replacement. Am J Med 1988; 85: 57-61. 41. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic 240 properties of antiphospholipid antibodies in mice. Circulation 1997; 96: 4380-4. 42. Rand JH, Wu XX, Quinn AS, Chen PP, Hathcock JJ, Taatjes DJ. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112 (5): 1687-95. 43. Rand JH, Wu XX, Quinn AS, Ashton AW, Chen PP, Hathcock JJ, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood 2010; 115 (11): 2292-9. 44. Petri M. Use of Hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13: 77-80. 45. Belizna C. Hydroxychloroquine as anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev 2015; 14: 358-62. 46. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2009; 68 (9): 1428-32. 47. Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 2013; 11 (10): 1927-9. 48. Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol 2013; 40 (1): 30-3. 49. Femia AN, Vleugels RA, Callen JP. Cutaneous dermatomyositis: an updated review of treatment options and internal associations. Am J Clin Dermatol 2013; 14 (4): 291-313. 50. Baughman RP, Lower EE. Medical therapy of sarcoidosis. Semin Respir Crit Care Med 2014; 35 (3): 391-406. 51. Carreño MA, Carvallo A, Trejo C, Ballestero F, Martínez C. Adult Still’s disease. A great simulator. Retrospective review of 20 patients. Rev Med Chile 2009; 137 (8): 1010-6. Rev Med Chile 2016; 144: 232-240


Febrero 2016
To see the actual publication please follow the link above